
PRESS RELEASE

Hovione Technology announces acquisition of global rights to new pulmonary inhaler device – the Papillon DPI

The ultra-affordable, multi-use blister DPI will be at Respiratory Drug Delivery, Lisbon

15 April 2019 – [Hovione Technology](#), a specialist in development of innovative inhalation device technology, has announced today it has secured global rights to develop and commercialize a new ultra-affordable, multi-use blister-based dry powder inhaler patented by inventor Dr. Klaus-Dieter Beller. The two parties will continue to collaborate on the inhaler, which will be marketed as the Papillon DPI.

The Papillon DPI is a single-part, blister-based, reusable inhaler of extreme simplicity, suitable for both chronic and acute treatments. It can accommodate a single or double blister configuration, enabling ultra-affordable drug therapies at global scale.

Papillon unlocks a paradigm shift for pharmaceutical companies developing new inhaled drugs: unit dose costs competitive to multi-dose inhalers at a fraction of the development cost and risk associated with complex devices.

Hovione Technology's CEO Peter Villax said, "This is a strategic DPI development for Hovione Technology which emphasizes our long-term commitment to offer market access to a portfolio of innovative inhalers that maximize simplicity of use, drug delivery performance and cost-effectiveness on a truly global scale. We are delighted to accelerate commercialization of this innovative blister DPI".

Hovione Technology has a co-promotional agreement with active pharmaceutical ingredient manufacturer [Hovione](#) and together they are able to provide access to a complete portfolio of innovative DPI devices integrated with inhalation API, formulation development and industrial manufacturing to pharmaceutical companies focusing on inhaled drugs.

About Hovione Technology

Hovione Technology offers access to a complete portfolio of innovative, cost-effective dry powder inhalation devices – disposable, capsule-based, blister-based and large dose DPIs. With over 20 years of expertise developing innovative inhaler technology, Hovione Technology's team has been behind the first market approved disposable dry powder inhaler, the TwinCaps DPI, marketed in Japan for treatment of influenza. This has become a notable success story resulting in millions of patients being treated every year with Hovione Technology's inhaler technology.

Peter Villax

CEO Hovione Technology
pvillax@hovionetechnology.com